Author
Laura J. Fochtmann
Bio: Laura J. Fochtmann is an academic researcher from American Psychological Association. The author has contributed to research in topics: Guideline & Psychological evaluation. The author has an hindex of 6, co-authored 8 publications receiving 438 citations.
Papers
More filters
TL;DR: The APA's most recent practice guideline on antipsychotic treatment in patients with dementia appears to have done just that, with a thorough, balanced, accurate, and current review of available treatments based on medical and scientific literature.
Abstract: Author(s): Reus, Victor I; Fochtmann, Laura J; Eyler, A Evan; Hilty, Donald M; Horvitz-Lennon, Marcela; Jibson, Michael D; Lopez, Oscar L; Mahoney, Jane; Pasic, Jagoda; Tan, Zaldy S; Wills, Cheryl D; Rhoads, Richard; Yager, Joel
266 citations
TL;DR: Victor I. Reus, M.D., Laura J. Fochtmann,M.P.H., Jane Mahoney, Ph.D, and Seung-Hee Hong (Systematic Review) are the authors of this systematic review of the determinants of hippocampal dissection in mice.
Abstract: Victor I. Reus, M.D., Laura J. Fochtmann, M.D., M.B.I., Oscar Bukstein, M.D., M.P.H., A. Evan Eyler, M.D., M.P.H., Donald M. Hilty, M.D., Marcela Horvitz-Lennon, M.D., M.P.H., Jane Mahoney, Ph.D., R.N., PMHCNS-B.C., Jagoda Pasic, M.D., Ph.D., Michael Weaver, M.D., Cheryl D. Wills, M.D., Jack McIntyre, M.D. (Consultant), Jeremy Kidd, M.D. (Consultant), Joel Yager, M.D. (Systematic Review), Seung-Hee Hong (Systematic Review)
183 citations
TL;DR: These Practice Guidelines for the Psychiatric Evaluation of Adults mark a transition in the American Psychiatric Association’s Practice Guidelines by using a “snowball” survey methodology to identify experts on psychiatric evaluation and solicit their input on aspects of the psychiatric evaluation that they saw as likely to improve specific patient outcomes.
Abstract: These Practice Guidelines for the Psychiatric Evaluation of Adults mark a transition in the American Psychiatric Association’s Practice Guidelines. Since the publication of the 2011 Institute of Medicine report Clinical Practice Guidelines We Can Trust, there has been an increasing focus on using clearly defined, transparent processes for rating the quality of evidence and the strength of the overall body of evidence in systematic reviews of the scientific literature. These guidelines were developed using a process intended to be consistent with the recommendations of the Institute of Medicine (2011), the Principles for theDevelopment of Specialty Society Clinical Guidelines of the Council of Medical Specialty Societies (2012), and the requirements of the Agency for Healthcare Research andQuality (AHRQ) for inclusion of a guideline in the National Guideline Clearinghouse. Parameters used for the guidelines’ systematic review are included with the full text of the guidelines; the development process is fully described in a document available on the APA website: http:// www.psychiatry.org/File%20Library/Practice/APA-GuidelineDevelopment-Process–updated-2011-.pdf. To supplement the expertise of members of the guideline work group, we used a “snowball” survey methodology to identify experts on psychiatric evaluation and solicit their input on aspects of the psychiatric evaluation that they saw as likely to improve specific patient outcomes (Yager 2014). Results of this expert survey are included with the full text of the practice guideline.
95 citations
22 Oct 2015
TL;DR: These Practice Guidelines for the Psychiatric Evaluation of Adults mark a transition in the American Psychiatric Association’s Practice Guidelines by using a “snowball” survey methodology to identify experts on psychiatric evaluation and solicit their input on aspects of the psychiatric evaluation that they saw as likely to improve specific patient outcomes.
Abstract: These Practice Guidelines for the Psychiatric Evaluation of Adults mark a transition in the American Psychiatric Association’s Practice Guidelines. Since the publication of the 2011 Institute of Medicine report Clinical Practice Guidelines We Can Trust, there has been an increasing focus on using clearly defined, transparent processes for rating the quality of evidence and the strength of the overall body of evidence in systematic reviews of the scientific literature. These guidelines were developed using a process intended to be consistent with the recommendations of the Institute of Medicine (2011), the Principles for theDevelopment of Specialty Society Clinical Guidelines of the Council of Medical Specialty Societies (2012), and the requirements of the Agency for Healthcare Research andQuality (AHRQ) for inclusion of a guideline in the National Guideline Clearinghouse. Parameters used for the guidelines’ systematic review are included with the full text of the guidelines; the development process is fully described in a document available on the APA website: http:// www.psychiatry.org/File%20Library/Practice/APA-GuidelineDevelopment-Process–updated-2011-.pdf. To supplement the expertise of members of the guideline work group, we used a “snowball” survey methodology to identify experts on psychiatric evaluation and solicit their input on aspects of the psychiatric evaluation that they saw as likely to improve specific patient outcomes (Yager 2014). Results of this expert survey are included with the full text of the practice guideline.
73 citations
17 Jan 2017
TL;DR: (Reprinted with permission from American Journal of Psychiatry 2016; 173:543-546).
Abstract: intervention as compared to other therapeutic options for the individual patient. The full text of the practice guideline includes a detailed description of expert consensus findings and research evidence related to effects of antipsychotic medication in individuals with dementia. It also describes aspects of guideline implementation that are relevant to individual patients’ circumstances and clinical presentation.
19 citations
Cited by
More filters
Journal Article•
TL;DR: It was noted that racial minorities were far less likely to receive routine medical procedures, were more likely to experience lower quality healthcare services, but more likely than other groups to receive lower limb amputations and other less desirable treatment options for diabetes and other conditions.
Abstract: Race and Health Outcomes: Historical Perspectives and Implications for Aphasia Outcomes • 2000 – Congress passed the Minority Health and Health Disparities Research and Education Act of 2000 (Public Law 106‐525) • Authorized the Institute of Medicine’s (IOM) landmark study “Unequal Treatment” documenting longstanding disparities in healthcare across a variety of settings and health conditions. • The report also noted that racial minorities were far less likely to receive routine medical procedures, were more likely to experience lower quality healthcare services, but more likely to receive lower limb amputations and other less desirable treatment options for diabetes and other conditions.
460 citations
TL;DR: Alcohol-related liver disease, alcohol-related steatohepatitis, and alcohol- related cirrhosis are suggested, retaining the familiar abbreviations (ALD, ASH, and AC, respectively), due to longstanding usage, the term alcoholic hepatitis will likely persist.
441 citations
TL;DR: Naltrexone, which can be given once daily, reduces the likelihood of a return to any drinking by 5% and binge-drinking risk by 10%.
Abstract: Importance Alcohol consumption is associated with 88 000 US deaths annually. Although routine screening for heavy alcohol use can identify patients with alcohol use disorder (AUD) and has been recommended, only 1 in 6 US adults report ever having been asked by a health professional about their drinking behavior. Alcohol use disorder, a problematic pattern of alcohol use accompanied by clinically significant impairment or distress, is present in up to 14% of US adults during a 1-year period, although only about 8% of affected individuals are treated in an alcohol treatment facility. Observations Four medications are approved by the US Food and Drug Administration to treat AUD: disulfiram, naltrexone (oral and long-acting injectable formulations), and acamprosate. However, patients with AUD most commonly receive counseling. Medications are prescribed to less than 9% of patients who are likely to benefit from them, given evidence that they exert clinically meaningful effects and their inclusion in clinical practice guidelines as first-line treatments for moderate to severe AUD. Naltrexone, which can be given once daily, reduces the likelihood of a return to any drinking by 5% and binge-drinking risk by 10%. Randomized clinical trials also show that some medications approved for other indications, including seizure disorder (eg, topiramate), are efficacious in treating AUD. Currently, there is not sufficient evidence to support the use of pharmacogenetics to personalize AUD treatments. Conclusions and Relevance Alcohol consumption is associated with a high rate of morbidity and mortality, and heavy alcohol use is the major risk factor for AUD. Simple, valid screening methods can be used to identify patients with heavy alcohol use, who can then be evaluated for the presence of an AUD. Patients receiving a diagnosis of the disorder should be given brief counseling and prescribed a first-line medication (eg, naltrexone) or referred for a more intensive psychosocial intervention.
348 citations
Journal Article•
TL;DR: In this paper, the authors compared the incidence of admissions to hospital for stroke among older adults with dementia receiving atypical or typical antipsychotics in Ontario, Canada, and found that older adults were more likely to experience stroke.
Abstract: To compare the incidence of admissions to hospital for stroke among older adults with dementia receiving atypical or typical antipsychotics.
Design: Population based retrospective cohort study.
Setting: Ontario, Canada.
patients: 32 710 older adults (⩾65 years) …
282 citations
TL;DR: There is a paucity of established evidence to guide treatment decision making in the case of clozapine-resistant schizophrenia, a subsample that represents a sizable proportion of those with schizophrenia.
Abstract: Objective:The present guidelines address the pharmacotherapy of schizophrenia in adults across different stages, phases, and symptom domains.Method:Guidelines were developed using the ADAPTE proces...
203 citations